WVA, Ceva announce new WVA Animal Welfare awardSeptember 20, 2018Following the World Veterinary Association (WVA) Animal Welfare Awards in 2017 and 2018, Ceva Santé Animale and WVA in collaboration with the International Veterinary Students Association will this year add a new category recognizing a veterinary student for his/her involvement and engagement in animal welfare. The WVA Animal Welfare Award 2019 will be presented to six selected veterinarians from the WVA's six geographical regions and to one veterinary student from around the world. The award ceremony will take place during the 35th World Veterinary Association Congress on April 28, 2019, in San Jose, Costa Rica. The aim of the WVA Animal Welfare Awards is to recognize and reward veterinarians who in their daily lives contribute to the protection and welfare of animals and have provided outstanding and exemplary welfare-related services to animals, animal owners, fellow veterinarians, and the public. "World Veterinary Association and Ceva Santé Animale recognize veterinarians and veterinary students for their exemplary work in protecting and promoting Animal Welfare," said the WVA in a statement. In addition, WVA and Ceva are hoping to expand the awards categories further to include veterinary schools in future editions, recognizing them for animal …
SPONSORED CONTENTSee What the ACVIM Recommends for Certain Types of Canine CHFSafe, effective treatment that's approved by the FDA for management of certain types of canine CHF. + Learn More
Synthetic Genomics, Ceva partner to develop livestock vaccinesNovember 1, 2017 Synthetic Genomics Inc. announced that it has partnered with Ceva Santé Animale to utilize Synthetic Genomics' next-generation synthetic RNA replicon platform to develop vaccines for livestock. Synthetic Genomics' RNA replicons are programed to deliver genetic instructions to a body's own cells to unleash a powerful immune response against a specific disease, the company said. These RNA replicons carry the genetic code for a self-replication engine as well as antigens that signal for an immune response. The self-amplifying, RNA-based vaccine triggers rapid and immediate antigen expression within host cells, which induces strong T cell and B cell responses. These fully synthetic vaccines have lower dose requirements and simplified manufacturing compared to traditional vaccine approaches, according to the announcement. "We have made tremendous progress to date in programming RNA to develop next-generation vaccines that are multigenic, tunable and, most importantly, scalable for commercially competitive markets such as animal health," said Synthetic Genomics CEO Dr. Oliver Fetzer. "This partnership with Ceva, a leader in animal health, highlights the promise in deploying our synthetic biology capabilities to build RNA systems capable of improving global health in a variety of ways." Financial terms of the agreement were not …
